Trial Profile
A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Temsirolimus (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms MAESTRO HN
- 04 May 2020 Results published in the Cancer
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Dec 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016, as per ClinicalTrials.gov record.